Indications for pancreatic cancer intervention: pancreatic cancer with liver metastases at the time of detection; liver metastases after surgery or other treatment for pancreatic cancer; failure of systemic chemotherapy for unresectable pancreatic cancer. For those with hepatic metastases, hepatic artery pancreatic cancer chemotherapy is administered by changing the dose of gemcitabine to hepatic artery (or hepatic metastasis donor artery) infusion of 1000 mg/m2 in the first week of each cycle, and gemcitabine 1000 mg/m2 over 30 minutes intravenously from the second week, once a week for 2 weeks, repeated on 28 days, for 2 cycles. In patients with primary pancreatic lesions, palliative local treatment of the pancreas was given after arterial chemotherapy if the general condition was good. Patients with all stages, such as those who have difficulty in surgical resection, or those with more concomitant lesions that are not suitable for surgery, or those who are unwilling to undergo surgery or other treatments, or those who have recurrence after surgery, can consider interventional treatment. In addition, patients with intermediate to advanced pancreatic cancer, who have obstructive jaundice, liver metastases, and severe back pain can also be considered. Regardless of pancreatic head cancer, pancreatic body cancer or pancreatic tail cancer, early or advanced cancer, whether or not surgery can be performed, and regardless of the mode of surgery, comprehensive treatment including selective arterial infusion chemotherapy should be actively performed.